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Abstract
Background: For the purpose of understanding the Food and Drug Administration’s (FDA’s) concerns regarding 
online promotion of prescription drugs advertised directly to consumers, this study examines notices of violations 
(NOVs) and warning letters issued by the FDA to pharmaceutical manufacturers. 
Methods: The FDA’s warning letters and NOVs, which were issued to pharmaceutical companies over a 10-year 
period (2005 to 2014) regarding online promotional activities, were content-analyzed. 
Results: Six violation categories were identified: risk information, efficacy information, indication information, 
product labeling, material information issues, and approval issues. The results reveal that approximately 95% of 
the alleged violations were found on branded drug websites, in online paid advertisements, and in online videos. 
Of the total 179 violations, the majority of the alleged violations were concerned with the lack of risk information 
and/or misrepresentation of efficacy information, suggesting that achieving a fair balance of benefit versus risk 
information is a major problem with regard to the direct-to-consumer advertising (DTCA) of prescription drugs. 
In addition, the character space limitations of online platforms, eg, sponsored links on search engines, pose 
challenges for pharmaceutical marketers with regard to adequately communicating important drug information, 
such as indication information, risk information, and product labeling. 
Conclusion: Presenting drug information in a fair and balanced manner remains a major problem. Industry 
guidance should consider addressing visibility and accessibility of information in the web environment to help 
pharmaceutical marketers meet the requirements for direct-to-consumer promotion and to protect consumers 
from misleading drug information. Promotion via social media warrants further attention, as pharmaceutical 
manufacturers have already begun actively establishing a social media presence, and the FDA has thus begun to 
keep tabs on social media promotions of prescription drugs. 
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Implications for policy makers
• Risk information is not easily accessible on the drugs’ websites, where unlimited pages and bandwidth space are available for information.
• Limited space, ie, sponsored links on search engines, on online venues often creates challenges for pharmaceutical marketers to adequately 
present product labeling and indication information.
• In the regulatory guidance for online direct-to-consumer advertising (DTCA), fair balance of information, as well as visibility and accessibility 
of information, should be considered to protect consumers from misleading information.
Implications for public
The online promotion of prescription drugs directly to consumers has become an increasingly popular method of drug advertising in the United 
States. Though the Food and Drug Administration (FDA) oversees direct-to-consumer advertising (DTCA) in order to protect consumers from 
misleading advertisements, some advertising may be violative because the promotional materials are not regulated by law before being aired in the 
market. Further, DTCA is more common for treatments for chronic conditions, which require regular prescriptions for a long battle, placing many 
vulnerable patients at risk. This study discusses the FDA’s concerns regarding online promotional activities of prescription drugs in an attempt to 
give context to pharmaceutical marketers on what to avoid in their online promotional materials, so that truthful and useful drug information is 
provided to consumers online.
Key Messages 
   View Video Summary
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Background
The online promotion of prescription drugs directly to 
consumers has become an increasingly popular method 
of drug advertising in the United States. Traditionally, 
pharmaceutical companies’ promotional efforts were directed 
almost exclusively to physicians and healthcare providers.1 In 
the 1990s, however, pharmaceutical manufacturers took their 
promotional efforts one step further and began marketing 
prescription drugs directly to consumers. At that time, the 
Food and Drug Administration (FDA) guidelines, which 
were tailored to print media, made it impractical to advertise 
prescription drugs in television commercials due to extensive 
disclosure requirements.1 In 1997, in response to advertisers’ 
needs in the pharmaceutical market and the changing media 
environment, the FDA updated its regulatory guidelines 
for broadcast direct-to-consumer advertising (DTCA) and 
clarified ways that information about prescription drugs 
could be presented in broadcast media, subsequently leading 
to an exponential increase in television commercials for 
prescription drugs.1 These new FDA guidelines thus opened a 
new marketing era, bringing with it broader opportunities for 
consumers to make informed decisions about health-related 
concerns, in addition to flooding the pharmaceutical market 
with DTCA.2
Consequently, pharmaceutical marketing expenditures 
for DTCA have increased rapidly since the end of the last 
millennium. For example, although the pharmaceutical 
industry spent $12 million on DTCA in 1989, its marketing 
expenditures skyrocketed to $2.38 billion in 2001, an almost 
200-fold increase in 12 years.2,3 Furthermore, in 2008, $4.7 
billion was spent on DTCA, accounting for almost one-fourth 
of the pharmaceutical companies’ marketing expenditures 
for all promotional activities.4 Due to new drugs being 
launched in the pharmaceutical market, DTCA spending 
reached its peak between 2004 and 2006, evidenced by the 
fact that the most heavily advertised drugs were also the top-
selling drugs in the US market.1 A recent study reported that 
pharmaceutical manufacturers continue to spend significant 
amounts on DTCA ($3.1 billion in 2012),5 although health 
professional-directed promotions are still dominant.
Currently, the DTCA of prescription drugs in broadcast and 
print media encourages consumers to visit drug websites 
for further information about the product.6 This allows 
advertisers to take advantage of online platforms and use 
more diverse approaches to reach consumers than was 
possible even a decade or two ago. They are actively engaging 
with consumers online and experimenting with new online 
media platforms, eg, social media, establishing an online 
presence and promoting their prescription drugs.7,8 However, 
as online advertising becomes an increasingly integral part 
of prescription drug promotion, the lack of clear guidance 
regarding online promotion has created challenges for 
pharmaceutical marketers.7
Therefore, based on an analysis of the alleged violations 
found in warning letters and untitled letters that have been 
issued to pharmaceutical manufacturers by the FDA in a 
recent 10-year span with regard to online DTC promotion of 
prescription drugs, the present study aims to diagnose issues 
that pharmaceutical marketers should avoid in their online 
promotional materials to protect consumers from misleading 
information. This study of FDA warning letters and notices of 
violations (NOVs) regarding alleged violations found in the 
online DTCA of prescription drugs appears to be unique in 
the literature at present. 
Literature Review
FDA Regulation of Prescription Drug Advertising
For the purpose of protecting public health, the FDA oversees 
prescription drug advertising to ensure that consumers receive 
accurate and science-based information about prescription 
drugs.9 The authority of the FDA includes determining 
whether the advertising contains any information that could 
possibly mislead consumers.9 However, according to federal 
law, the FDA may not compel pharmaceutical companies 
to submit prescription drug-related DTCA for approval; 
rather, many drug companies are encouraged to seek advice 
from the FDA voluntarily before releasing their ads. This 
current scenario indicates that the public could see ads that 
may include false or misleading information before the FDA 
can take action on any unlawful claims the pharmaceutical 
companies may have made in their advertisements.10
In order to regulate drug companies’ marketing activities, the 
usual policy is for the Office of Prescription Drug Promotion 
(OPDP) within the FDA to send letters to pharmaceutical 
companies and request that they remove ads or stop unlawful 
promotional activities if the OPDP alleges that their ads 
violate the law.10 Generally, the FDA finds that the DTCA 
of prescription drugs is allegedly unlawful if such ads state 
or imply that unproven drugs can treat a condition, claim 
benefits without providing adequate evidence, falsely 
represent data from studies, overstate efficacy, or omit or 
downplay risk information.10 The OPDP issues 2 types of 
letters to pharmaceutical companies to notify them of alleged 
violations.2 One is a NOV, also called an untitled letter, and 
the other is a warning letter. Untitled letters are sent to drug 
companies for minor violations, whereas warning letters are 
issued for serious violations and imply that the FDA will 
proceed with further regulations if the cited company does 
not take corrective action or respond to the FDA.2
Specifically, the FDA’s authority over prescription advertising 
is based on the Food, Drug, and Cosmetic (FDC) Act, which 
requires that prescription drug advertising must present 
information in a way that is accurate and in a non-misleading 
manner.9 Also, the FDA’s Center for Drug Evaluation 
and Research (CDER) is responsible for ensuring that 
pharmaceutical manufacturers present drug information in a 
valid and balanced manner in their claims.9 Pharmaceutical 
marketers must present both the benefits and risks of a drug in 
a fair and balanced manner11 and similarly in terms of content 
and presentation.12 In other words, the most important risk 
information should not be minimized in comparison to 
the efficacy claims, because prescription drugs may cause 
substantial side effects to some patients, even though they 
may also provide effective medical benefits.13
According to the FDA’s regulations regarding the DTCA of 
prescription drugs, advertisements must comply with the 
“brief summary” or the “major statement,” which requires that 
promotional materials provide information that relates to side 
effects, contraindications, and effectiveness.13 The FDA has 
been monitoring whether DTCA presents adequate contextual 
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and risk information with understandable language in a fair 
and balanced manner in an attempt to ensure that consumers 
receive non-misleading promotional claims. Although the 
FDA has recognized the importance of the Internet as a 
growing marketing channel for pharmaceutical companies, 
the agency has expressed concerns as to how to best achieve 
fair balance in the DTCA of prescription drugs in an online 
environment.14,15 The growing number of available online 
DTCA platforms, including social media posts, banner ads, 
embedded videos, and sponsored links on search engines, 
makes it increasingly difficult for the FDA to monitor and 
regulate all such promotional activities. In an effort to address 
these concerns, in 2013, the FDA introduced draft guidelines 
for consumer-directed online promotional activities,15 and 3 
other draft guidelines were added in 2014.14,16,17 However, it 
appears that these draft guidelines do not comprehensively 
address concerns related to online prescription drug 
promotions advertised directly to consumers.7
Consumer Advantages and Disadvantages of Direct-to-Consumer 
Advertising of Prescription Drugs 
DTCA helps consumers have better discussions with their 
physicians and to make better health-related decisions as 
active consumers.13,18 Prescription drug advertising can be 
useful in that it enables consumers to pay closer attention 
to their health conditions and learn about new medications 
and treatment options.19 DTCA arguably lessens the stigma 
associated with many health concerns and diseases, thereby 
making it easier for consumers to discuss such private matters 
with their doctors and seek treatment,2 while reducing 
unnecessary surgeries and hospitalization, which lowers 
overall healthcare costs.20 
Despite the various benefits of DTCA, some have expressed 
considerable concern regarding the DTCA of prescription 
drugs due to the inadequate presentation of information in 
the ads, which could result in adverse effects for consumers. 
For instance, DTCA may cause unnecessary anxiety, in that 
frequent exposure to such information makes people overly 
concerned about their health.21 Notably, the major problem 
associated with DTCA is that advertisers often overemphasize 
the efficacy of a prescription drug while minimizing the risks 
associated with the drug’s use, which leads patients to conclude 
that certain brands of drugs are more effective and safer than 
others, or that certain brands have only minor risks.18 As an 
example, models in ads for HIV medications are portrayed 
as healthy-looking people who actively engage in social 
activities, downplaying the cause of HIV while highlighting 
aspirational images.22 Visual cues in ads serve an important 
persuasive role,22 and the portrayal of drugs and medical 
conditions in DTCA can be problematic and misleading in 
this regard. Thus, given these considerations, the following 
sections discuss the key concerns that have been raised with 
regard to DTCA in both traditional media and online media.
Achieving a Fair Balance of Information in Direct-to-Consumer 
Advertising of Prescription Drugs 
The primary key area of concern regarding prescription drugs 
advertised directly to consumers is that of fair balance, ie, a 
balanced presentation of the benefits and the risks of the 
drugs being advertised. This issue has been ongoing since 
DTCA became available in broadcast and print media. For 
example, a study focusing on the warning letters and untitled 
letters that the FDA issued to drug advertisers with regard 
to DTCA in broadcast and print media reveals that about 
38% of the complaints centered on the fair balance issue.20 
The thrust of the complaints is that failing to achieve fair 
balance is primarily due to the lack or minimization of risk 
information in the allegedly violative ads.20 The commercials 
on broadcast media, where product claims are made in 
a limited length of time (30 to 60 seconds), often do not 
adequately communicate side effects, contradictions, and 
precautions, which presumably could mislead consumers.21 
The inadequate presentation of risk information in DTCA 
can negatively affect consumers by making it difficult for 
them to understand the side effects of the drugs that are being 
promoted in televised DTCA.20,23 
One reason that pharmaceutical marketers may fail to 
present information about their drugs in a fair and balanced 
manner might be the lack of explicit guidelines as to ways 
they can achieve a balanced presentation of benefit and risk 
information.20 The more recent addition of online DTCA 
to existing broadcast and print media DTCA has created 
even more challenges for the FDA to ensure the balanced 
presentation of pharmaceutical information to the public.7
Direct-to-Consumer Advertising of Prescription Drugs on 
the Internet
The pharmaceutical industry is moving forward rapidly into 
online marketing, as online media platforms allow marketers 
to reach a larger number of consumers than traditional forms 
of media, help target specific patients, and are more cost 
efficient than TV or print.7,24 In order to promote prescription 
drugs directly to consumers online, pharmaceutical 
manufacturers have spent their advertising budgets on online 
banners, streaming videos, sponsored ads on search engines, 
and product websites.1 Among these online promotion 
types, prescription drug websites now serve as a primary 
source for consumers to obtain a variety of information 
about prescription drugs in detail, such as testimonials from 
the drug’s users, assessment tools, and the drug’s risks and 
benefits.25 Because the FDA permits broadcast DTCA to refer 
consumers to a brand’s website, print advertisements, or a toll-
free telephone number, the brand websites for prescription 
drugs thus have become venues that consumers can visit to 
seek further information about particular drugs.23 
Interestingly, however, studies have revealed that nearly half 
of these websites did not actually include risk information 
about the drugs being advertised.25 Furthermore, any risk 
information included often was not designed or presented 
in a way that was similar to the benefit information. More 
significant, the risk information was not explicitly visible; for 
example, visitors to the site were forced to scroll down to see 
it, which could minimize the chance of consumers seeing the 
information at all.25 In a similar vein, another study showed 
that the benefit information was presented in a way to attract 
more attention from the viewer, whereas the risk information 
was less eye-catching.26 Thus, pharmaceutical marketers 
often fail to address risk information as adequately on their 
websites as they did when they advertised in broadcast and 
print media. 
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In a recent study examining pharmaceutical manufacturers’ 
social media presence for their prescription drugs, all top 10 
pharmaceutical corporations were found to have Facebook 
pages and Twitter feeds.7 In addition, 8 companies had 
dedicated YouTube channels and healthcare-related mobile 
applications, suggesting that pharmaceutical marketers 
are actively adopting digital channels as marketing tools.7 
With the growing use of digital channels as prescription 
ad platforms, the FDA has begun to express concerns and 
send preemptive warning letters to major pharmaceutical 
companies advising them to stop placing sponsored link 
ads on search engines in a misleading way—ie, omitting risk 
information.27 What’s more, social media can be an incredibly 
complex form of media, in that marketers are unable to 
completely control their marketing messaging;7 thus, scholars 
posit that alternative regulatory policy, eg, independent third-
party oversight, is necessary to ensure public safety.24
Research Questions
Online media platforms provide many opportunities for 
pharmaceutical manufacturers to promote prescription 
drugs directly to consumers. Simultaneously, however, this 
information can be misleadingly delivered to consumers, 
threatening public health. Therefore, the goal of this study 
is to understand the FDA’s concerns with regard to the 
online DTCA of prescription drugs by examining the 
FDA’s warning letters and untitled letters that have been 
issued to pharmaceutical companies. This study identifies 
the most common alleged violations that pharmaceutical 
manufacturers often make in their online promotional 
activities, and thus addresses the following research questions. 
RQ1. What types of online promotional platforms received 
the most letters from the FDA?
RQ2. What are the drug categories that have been the subject 
of FDA warning and untitled letters?
RQ3. What types of legal violations does the FDA allege most 
frequently occur in the online DTCA of prescription drugs?
RQ4. How do the types of alleged violations differ by online 
promotion type?
Methods
This analysis is based on the warning letters and NOVs issued 
by the FDA from 2005 through 2014 concerning the online 
DTCA of prescription drugs. The present study examined 
FDA letters over a recent span of 10 years when scholars 
began to pay particular attention to drug manufacturers’ 
online promotional activities with regard to prescription 
drugs. Since the last time the FDA’s warning letters with 
regard to traditional media—broadcast and print—were 
studies in 2003,20 2 new studies focusing on online media 
have come out: Huh and Cude26 investigated the fair balance 
issue in direct-to-consumers prescription drug websites in 
2004, and another similar study was published by Sheehan in 
2007.25 Therefore, for the purpose of expanding the current 
discussion of drug manufacturers’ online promotional 
activities, the present study examined alleged violations of 
prescription drug promotions from 2005 to 2014.
These letters are publically accessible and available from 
the FDA’s website. A total of 262 letters were downloaded. 
First, letters were categorized as being related to consumer-
directed online promotion (73 letters), consumer-directed 
traditional media promotion (48 letters), and healthcare 
professional-directed promotion (141 letters). As this study 
is only concerned with online DTCA, the consumer-directed 
traditional media and healthcare professional-directed 
promotion category letters were discarded.
The letters that were issued for online promotional activities 
only were then content-analyzed into subcategories based on 
online promotion type, drug category, and type of alleged 
violation. The majority of located letters contained multiple 
alleged violations; thus, 179 allegations of violations were 
counted in total. Only 11 letters identified a single alleged 
violation. The rest of letters reported 2 or more violations: 
24 letters with 2 violations, 32 letters with 3 violations, and 6 
letters with 4 violations. 
Two coders coded the letters to ensure inter-coder reliability. 
Coders were trained to increase inter-coder reliability and 
coded the data according to a structured coding scheme; 
further, they were instructed to examine both actual 
promotional materials and letters to correctly code the data 
into relevant categories. These actual promotional materials 
were also downloaded from the FDA website, along with 
the letters. Krippendorff ’s α was used for the inter-coder 
reliability check.28 Krippendorff ’s α for the variables ranged 
from 0.82 to 1.0. 
The coding protocol was developed based on Sheehan’s 
study, which examined FDA warning letters regarding 
DTCA violations in traditional media.20 The coding 
protocol included (1) issue date, (2) name of drugs, (3) drug 
categories, (4) online promotion type, and (5) categories of 
alleged violation. Coders were instructed to initially look at 
subheadings of violations to determine relevant categories 
when coding violations. Coding for online promotion type 
was easily identifiable because the FDA addressed the type of 
media they were investigating in the introductory paragraph 
of the letters. 
Types of online promotion were categorized into website, 
online paid ads, online video, email, and social media. 
Promotional materials on manufacturers’ websites were 
promotional messages or drug information including 
text and graphics. Online paid ads included text ads (ie, 
sponsored links) on search engine sites such as Google and 
online banner ads. One type of online video promotion was 
a video clip embedded in a manufacturer’s website, either in 
the form of patients’ testimonials or as an online video ad. 
Another type of online video promotion was a YouTube 
video clip uploaded by a drug manufacturer in the form 
of a video ad to be included as video streaming content on 
nondrug manufacturers’ sites. Email was the electronic mail 
sent to consumers by pharmaceutical marketers. Social media 
promotions for the purpose of this study were mainly related 
to Facebook, ie, Facebook pages and the Facebook “share” 
button on a manufacturer’s website. 
Online promotion types were then grouped into 2 categories: 
market-controlled and market-influenced. Market-controlled 
promotions are websites, online paid ads, online videos, and 
emails in which marketers have full control of their marketing 
messaging. By contrast, drug manufacturers are unable to 
fully control their promotional activities on social media 
because social media platforms specifically enable consumers 
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add their own messages and share information with fellow 
consumers.7 In fact, the FDA has indeed expressed concerns 
about the uncontrollability of social media promotional 
materials in its letters.29,30
These violations were then grouped into 6 categories: risk 
information, indication information, efficacy information, 
product labeling, approval issues, and material information 
issues. In categorizing the alleged violations, Sheehan’s 
categories of complaints from her 2003 study were 
employed,20 with the addition of categories for indication 
information and product labeling. According to Sheehan’s 
types of complaints,20 alleged violation of risk information is 
concerned with the omission of important risk information 
and minimization of risk information. If the letters cited a 
violation because the material in question did not disclose 
or clearly state risk information, it was coded as omission 
of risk information, whereas it was coded as minimization 
of risks when the promotional material downplayed the 
seriousness of risks. Complaints about efficacy information 
are often associated with misleading communication about 
the benefits of drugs, such as an overstatement of benefits 
or unsubstantiated claims of efficacy. Approval issues were 
coded when the pharmaceutical companies promoted drugs 
that were under investigation. Material information was 
used to indicate the type of complaints related to misleading 
communication of ingredients information for the drugs. 
Violation of product labeling, a newly added complaint 
category, was often related to sponsored links on a search 
engine. The FDA invoked this complaint when the drug 
manufacturers failed to adequately present both the generic 
name and brand name of the drug. Another newly added 
complaint category was indication information, aimed at 
material which misleadingly communicated drugs’ dosage 
instructions by broadening the patients types who should be 
taking the drugs or failing to adequately present when and 
how to take the drugs to ensure safety.
Results
Ten Years (2005 to 2014) of FDA Allegations of Violative 
Direct-to-Consumer Advertising in Online Media
Seventy-three warning letters and NOVs were collected for 
analysis. Alleged violations were found in a variety of online 
promotion types. Approximately half of the letters were 
issued by the FDA for advertisements on drug websites. 
About 25% of the violations were found in the online paid 
ad category, such as banner ads and text ads. The letters that 
were issued for online video promotion accounted for 22% of 
the total number of letters (see Table 1). Thus, the majority 
(94.5%) of violations were related to promotional materials 
in these 3 media platform categories. Notably, over the 10 
years in the time range for this study, 5 warning letters were 
issued concerning advertisers’ promotional activities on 
brand websites and 3 warning letters were sent concerning 
online videos. Thus, it appears that the FDA has expressed 
considerable concern over promotional materials on drug 
companies’ websites and online videos when determining 
alleged violations. Therefore, RQ1 was addressed.
Interestingly, the results revealed that pharmaceutical 
companies use email (2 letters were found) in an attempt to 
reach specific individuals. Social media widgets, the Facebook 
“share” button on a webpage, are also used by pharmaceutical 
marketers to encourage consumers to engage in the content 
and propagate messages.
In general, DTCA is more common for drugs intended to 
treat chronic condition, serving as a reminder for prescription 
refill.1,7 As such, pharmaceutical manufacturers target this 
market, where larger number of patients regularly ask for 
prescriptions for extended periods of time.1,7 The finding 
in the present study indicated that about 22% of the letters 
examined were issued for cancer treatment drugs (see 
Table 2). Thus, RQ2 was addressed.
Next, among the 6 violation categories, alleged violation 
of risk information was the most frequently reported, 
followed by efficacy information and indication information 
(see Table 3). It also appeared that alleged violation of risk 
information went hand in hand with efficacy information, 
meaning that pharmaceutical marketers seemed to downplay 
risk information for the sake of emphasizing the benefits of 
their drugs. For some letters, the FDA claimed both omission 
and minimization of risk information when addressing alleged 
violation of risk information. The most serious problem of 
alleged violation of efficacy information was overstating the 
efficacy of drugs and claiming benefits without providing 
substantiated evidence. The alleged violation of indication 
information was newly added in the present study, as it was 
not found in DTCA in traditional media in Sheehan’s 2003 
study. Specific problems found in this violation category were 
inadequate communication of drug indication regarding 
dosage instructions and broadening patient types eligible to 
take the drugs. These results addressed RQ3.
Finally, RQ4 asks whether the types of alleged violations differ 
by online promotion type. As shown in Table 4, specific alleged 
violations were more frequently reported in certain types of 
online promotional activities. For example, the majority of 
Table 1. Types of Online Promotion Warned by the FDA
Online Promotion Category Types of Promotion No. Percent
Marketer controlled
Website Website/webpage 35 47.9
Online paid ad Sponsored links in Internet search engines/banner ads 18 24.7
Online video
Embedded testimonial videos or promotional videos on manufacturers’ websites 14
21.9
Promotional online video on independent websitesa 2
Email Email promotion 2 2.7
Marketer influenced Social media
Social media widgets (Facebook “Share" button) on drug manufacturers’ websites/
Facebook pages
2 2.7
Total 73 99.9
Abbreviation: FDA, Food and Drug Administration.
a One promotional video was a YouTube video clip uploaded by a drug manufacturer and the other video was and online video ad placed as video streaming 
news content on CNN.
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Table 2. Types of Drugs Receiving FDA Warning or Untitled Letters
Drug Category No. Percent
Cancer 16 21.9
Dermatological conditions 9 12.3
Urological conditions 5 6.8
Cardiovascular disease 5 6.8
Psychiatric/neurological disorders 4 5.5
Musculoskeletal ailment 4 5.5
OB/GYN conditions 3 4.1
HIV-AIDS 3 4.1
Gastrointestinal conditions 3 4.1
Infections/non-HIV disease 3 4.1
High cholesterol 3 4.1
Allergy 2 2.7
Arthritis 2 2.7
Depression 2 2.7
Diabetes 2 2.7
Osteoporosis 2 2.7
Respiratory condition 1 1.4
Weight loss 1 1.4
Hypotrichosis of eyelash 1 1.4
Serious pain relief 1 1.4
Tobacco addictions 1 1.4
Total 73 99.8
Abbreviations: OB/GYN, obstetrics and gynecology; FDA, Food and Drug 
Administration.
Table 3. Types of Alleged Violations
Category of Alleged Violation Details of Alleged Violation No. Percent
Risk information Subtotal 58 32.4
Omission of risk information 39 21.8
Minimization of risk information 19 10.6
Efficacy information Subtotal 51 28.5
Overstatement of efficacy 25 14.0
Unsubstantiated claims 12 6.7
Unsubstantiated superiority claims 10 5.6
Misleading claims 4 2.2
Indication information Subtotal 34 19.0
Inadequate communication of indication 15 8.4
Broadening of indication 12 6.7
Misleading communication of the indication 3 1.7
Failure to state full indication 1 0.6
Misleading claims regarding dosing 1 0.6
Unsubstantiated dosing claims 1 0.6
Omission of indication information 1 0.6
Product labeling Subtotal 14 7.8
Failure to use required established name 14 7.8
Material information issues Subtotal 13 7.3
Omission of material facts 10 5.6
Misleading presentation 3 1.7
Approval issues Subtotal 9 5.0
Promotion of an investigational new drug/promotion of unproved use 9 5.0
Total 179 100
online paid ads allegedly failed to present product labeling 
and indication information adequately, whereas online video 
promotions often omitted or misrepresented risk information 
(see Table 4). Thus, RQ4 was addressed. 
In order to provide context for each alleged violation with 
regard to the online promotion of prescription drugs, the 
following sections provide detailed analysis regarding 
the top 4 alleged violations, ie, risk information, efficacy 
information, indication information, and product labeling, 
which accounted for approximately 88% of the total alleged 
violations. 
Risk Information
The FDA alleges a policy violation when the advertisement 
fails to communicate a drug’s risk information correctly 
by omitting or minimizing the side effects associated with 
the drug.31 For instance, in a 2006 warning letter issued to 
BioMarin Pharmaceutical regarding its FDA-approved drug 
Orapred, a prescription treatment for allergic conditions in 
asthma patients, the FDA alleged that the company’s website 
for the drug was in violation because it contained efficacy 
claims but the risk information was not easily accessible. 
Also, a NOV was issued to KV Pharmaceutical for its email 
promotion because the benefit claims were conspicuously 
presented using large, bold headers with bullets, whereas all 
the risk information was at the end of the email, using smaller 
font without any bolding or bullet points. 
Findings in this study revealed that the risk information for 
drugs was not always communicated adequately in terms of 
format, quantity, location, or even its level of seriousness. 
According to the FDA, the risk information, when compared 
to the benefit information, was displayed less prominently 
in online promotional materials. Most important, the 
FDA expressed concern in its letters that the lack of risk 
information or inadequate presentation of such information 
could mislead consumers by possibly causing them to believe 
that the advertised drug has more benefits than risks, which 
could ultimately threaten public health. 
Efficacy Information
In general, the FDA considers promotional materials to be 
misleading if advertisers tout a drug as superior to other 
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alternatives without basing this claim on adequate, well-
controlled clinical trials and substantiated comparisons 
with competitors in addressing the safety and effectiveness 
of the product.32 For instance, in a warning letter issued 
for inadequate claims of superiority, the FDA alleged 
that Adderall XR’s video testimonial posted on YouTube 
misleadingly implied that Adderall XR was more likely than 
its competitors to treat attention deficit hyperactivity disorder 
(ADHD) symptoms without providing substantial evidence 
to support such claims in the video. This violation type was 
found most frequently on companies’ websites, followed by 
online videos (see Table 4). The FDA specifically expressed 
public health and safety concerns about benefit claims 
that overstate or inflate efficacy without providing clinical 
evidence that would ensure the safety of the drugs.
Indication Information
Alleged violations of the inadequate communication of 
indication were frequently found in sponsored links on 
search engines, where advertisers needed to communicate 
key messages within the limited space allowed on the search 
engine websites.
According to the NOV the FDA issued to Pfizer in 2009, 
one of Pfizer’s sponsored links provided incomplete content 
about dosage information for their product Aromasin. The 
FDA alleged in this letter that Aromasin’s sponsored link 
broadened the indication, implying that the promoted drug 
was available for treatment of the broader female population, 
although the drug treatment was limited to only a specific 
type of patient, ie, postmenopausal women. Similarly, a letter 
regarding Orapred, a medication approved to treat only severe 
allergic conditions for adult and pediatric populations with 
asthma or respiratory disorders, found that the drug’s website 
described only the general condition of asthma, implying 
that Orapred was useful for a broad range of conditions and 
patients, thereby failing to describe important limitations 
regarding Orapred’s indication. 
Product Labeling
The FDA warning letters and NOVs indicated that many 
sponsored links, ie, text ads on search engines, allegedly 
failed to use the required established name of the drug being 
promoted. According to FDA regulations, the established 
name, or generic name, that includes the active ingredients 
of the drug, must accompany the proprietary name, which is 
the drug’s brand name. In order to provide details about the 
drugs to consumers, the established name should be placed 
to the right of or below the proprietary name.15 Based on 
the requirements for the presentation of prescription drugs’ 
product names, including the size, placement, and frequency 
of  labeling and advertising, the FDA alleged that the 
sponsored links inadequately presented the product name, 
thereby misrepresenting the particular drug’s established 
name (see Table 4). In addition, these sponsored links were 
the most frequently associated with alleged violations of the 
risk and indication information presentation requirements. 
The lack of risk information or inadequate presentation 
of indication information may be attributed to the limited 
advertising space in sponsored links. 
Discussion 
This study examined the FDA’s concerns with regard to 
online promotional activities of prescription drugs advertised 
directly to consumers. The FDA’s warning letters and NOVs, 
which were issued to pharmaceutical manufacturers over a 
recent span of 10 years, were thus content-analyzed. 
The results indicate that nearly 95% of the alleged violations 
were found in promotional content from branded drug 
websites, online paid ads, and online videos. The FDA 
expressed considerable concern over online promotion of 
cancer treatments, which require regular prescriptions for 
long-term treatment. The most significant finding, that 
concerning the fair balance issue, suggests that the online 
promotional content of prescription drugs fails to present 
risks and benefits in a balanced manner. This issue has also 
been a primary concern for traditional forms of media, 
such as broadcast media and print media,20 suggesting that 
presenting drug information in a fair and balanced manner 
remains a major problem. 
New forms of advertising platforms have been accompanied 
by new violations as well. For instance, due to limited 
character space, sponsored ads on search engines frequently 
fail to state a drug’s correct indication information fully 
or to present the product names as adequately as the law 
requires by not correctly communicating both the brand 
name (proprietary name) and the generic name (established 
name). These failures could result in safety concerns, because 
the lack of indication information and active ingredient 
information could lead to misuse of the drug. The FDA 
expresses particular concern about sponsored links on search 
engines, as evidenced by preemptive untitled letters sent to 
major pharmaceutical manufacturers in 2009 to advise drug 
advertisers about the need for the adequate presentation of 
product labels.27 As a result, the FDA published draft guidelines 
for this type of advertising, providing guidance about ways 
to present drug information, specifically risk information 
associated with drug usage, on sponsored links where 
advertising space is relatively limited.15 In the draft guidelines, 
Table 4. Types of Alleged Violations by Online Promotion Type
Category of Alleged Violation Website Online Paid Ad (Text/Banner) Online Video/Webcast Social Media Email
Risk information 27 16 15 2 2
Efficacy information 26 1 11 2 1
Indication information 13 12 6 1 2
Product labeling 1 15 0 0 1
Approval issues 6 0 2 0 0
Material information issues 8 1 2 2 0
Total 81 45 36 7 6
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the FDA acknowledges that character space limitations on 
online platforms might pose challenges for pharmaceutical 
manufacturers in delivering both benefits and risks in a fair 
and balanced manner. This guidance therefore specifically 
addressed the importance of the adequate presentation of 
risk information that could prevent consumers from viewing 
misleading drug information.15
In addition, the FDA is increasingly concerned over the 
growing popularity of social media as a pharmaceutical 
marketing channel, as evidenced by the recent industry 
guidance for social media published in 2014. However, 
researchers have suggested that the guidelines do not 
adequately troubleshoot issues pertaining to social media 
marketing.24 Though only 2 letters were found regarding 
social media promotions in this study, top pharmaceutical 
manufacturers have already been developing their social 
media presence, actively adopting social media in their 
marketing communication strategy.7,24 Moreover, their 
Facebook pages appear to be accessible to non-US consumers, 
although the pages do indicate that they are designated only 
for US consumers, creating further regulatory concerns.7,33 
According to the letters studied, the FDA specifically 
expressed concerns about the uncontrollability of social 
media, in that regulators can hardly oversee content created 
by consumers on social media and message-sharing through 
the media, which makes it difficult for marketers to predict a 
message’s viral impact. 
Pharmaceutical marketers are also trying to reach specific 
patients through personal email, and the FDA finds that 
important risk information and indication information 
are not adequately communicated in email promotions. 
In general, consumers perceive individually tailored 
promotional materials as easier to understand and more 
attention-catching than non-tailored ones;34 thus, promotional 
emails that are sent individually to specific patients can be 
quite problematic with regard to fair balance issues. It is clear 
that pharmaceutical marketing through social media and 
tailored emails warrants close attention and further research 
to respond to growing industry inquiries.
Online platforms allow pharmaceutical manufacturers 
to create content in a variety of formats. Benefit and risk 
information about drugs can be presented in different 
ways, too. It is possible to overstate benefit information by 
presenting efficacy information on the first page of a website, 
for example, or by using larger font in an email. By the same 
token, the risks of a drug can be perceived as less significant 
if the information is presented in a smaller font or requires 
many clicks to reach the relevant page. Although prescription 
drugs provide many benefits to patients, they also may be 
accompanied by serious risks.24 Due to the side effects that 
might affect some patients significantly, prescription drugs 
traditionally have been prescribed by and their use advised 
under the guidance of physicians. As the present study 
indicates, it is still challenging to present risk information 
adequately on online platforms. 
Consumers acquire information either poorly or well 
depending on the way the information is presented.35 In 
fact, different types of information presentation on online 
platforms significantly affect consumers’ perceptions and 
attitudes differently. For example, animated banner ads, as 
opposed to static banner ads, lead to higher recall, click intent, 
and a positive attitude toward the ads due to their attention-
grabbing capabilities.36 Moreover, the visual appeal of website 
designs for the DTCA of prescription drugs may impede 
people’s ability to process information correctly.37 Therefore, 
the inadequate presentation of drug information could result 
in informed but unsafe healthcare decisions and put public 
health and safety at risk.25 In this vein, the FDA has insistently 
warned about visibility and accessibility of information in 
the online environment. It is increasingly clear that merely 
requesting that drug marketers present balanced information 
may not provide an ideal system of guidance in the online 
environment; rather, comprehensive guidelines that address 
the accessibility and visibility of information would help 
pharmaceutical marketers avoid putting so many misleading 
promotional activities online.
This study, however, has some limitations worth noting. One 
potential limitation of this study is that the letters issued by 
the FDA are only allegations of violations and not findings 
by a court. Second, the results are descriptive and do not 
represent all the online marketing issues with regard to DTCA 
in the pharmaceutical market. Despite these limitations, the 
present study does make meaningful contributions to the 
current discussion of online promotion of prescription drugs 
being advertised directly to consumers by identifying the 
FDA’s concerns as revealed by their recent warning letters 
and NOVs. Furthermore, the findings from the current study 
provide pharmaceutical marketers with a note of caution 
about common mistakes to avoid in online promotions in 
order to meet the regulatory requirements while protecting 
consumers from misleading information.
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